EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Joanna Pozniak, Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Asier Antoranz, Lukas Vanwynsberghe, Ada Nowosad, Niccolò Roda, Samira Makhzami, Greet Bervoets, Lucas Ferreira Maciel, Carlos Ariel Pulido-Vicuña und 27 weitere

Cell · 2024-01 · 187 (1) · 166-183.e25

DOI: 10.1016/j.cell.2023.11.037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-01. Verfasst von Joanna Pozniak und 38 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium. Electro…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 231-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Melanoma Research Foundation, Vlaams Supercomputer Centrum, Stichting Tegen Kanker.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To better understand intrinsic resistance to immune checkpoint blockade (ICB), we established a comprehensive view of the cellular architecture of the treatment-naive melanoma ecosystem and studied its evolution under ICB. Using single-cell, spatial multi-omics, we showed that the tumor microenvironment promotes the emergence of a complex melanoma transcriptomic landscape. Melanoma cells harboring a mesenchymal-like (MES) state, a population known to confer resistance to targeted therapy, were significantly enriched in early on-treatment biopsies from non-responders to ICB. TCF4 serves as the hub of this landscape by being a master regulator of the MES signature and a suppressor of the melanocytic and antigen presentation transcriptional programs. Targeting TCF4 genetically or pharmacologically, using a bromodomain inhibitor, increased immunogenicity and sensitivity of MES cells to ICB and targeted therapy. We thereby uncovered a TCF4-dependent regulatory network that orchestrates multiple transcriptional programs and contributes to resistance to both targeted therapy and ICB in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansGene Regulatory NetworksImmunotherapyMelanocytesTranscription Factor 4Tumor Microenvironment

Stichwörter der Autor:innen

BET inhibitionEMTTCF4antigen presentationcheckpoint immunotherapydedifferentiationintra-tumor heterogeneitymelanomasingle-cell transcriptomicstumor microenvironment

Substanzen

TCF4 protein, humanTranscription Factor 4

Autor:innen und Institutionen

  • Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: joanna.pozniak@kuleuven.be.
  • Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Membrane Trafficking, Center for Brain and Disease Research, V…
  • Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, UZ Leuven, Leuven, Belgium.
  • Department of General Medical Oncology, UZ Leuven, Leuven, Belgium.
  • Laboratory of Translational Cell and Tissue Research, Department of Imaging and Pathology, KU Leuven and UZ Leuven, Leuven, Belgium.
  • Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.

Förderung

  • Melanoma Research Foundation
  • Vlaams Supercomputer Centrum
  • Stichting Tegen Kanker
  • European Commission
  • Melanoma Research Alliance
  • Alexander von Humboldt-Stiftung
  • Université Catholique de Louvain
  • Kom op tegen kanker

Zitieren

APA

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., Maciel, L. F., Pulido-Vicuña, C. A., Pollaris, L., Seurinck, R., Zhao, F., Flem-Karlsen, K., Damsky, W., Chen, L., Karagianni, D., …, & Marine, J. C. (2024). A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell, 187(1), 166-183.e25. https://doi.org/10.1016/j.cell.2023.11.037

Vancouver

Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187(1):166-183.e25. doi:10.1016/j.cell.2023.11.037

BibTeX
@article{Pozniak2024,
  author = {Pozniak, Joanna and Pedri, Dennis and Landeloos, Ewout and Van Herck, Yannick and Antoranz, Asier and Vanwynsberghe, Lukas and Nowosad, Ada and Roda, Niccolò and Makhzami, Samira and Bervoets, Greet and Maciel, Lucas Ferreira and Pulido-Vicuña, Carlos Ariel and Pollaris, Lotte and Seurinck, Ruth and Zhao, Fang and Flem-Karlsen, Karine and Damsky, William and Chen, Limin and Karagianni, Despoina and Cinque, Sonia and Kint, Sam and Vandereyken, Katy and Rombaut, Benjamin and Voet, Thierry and Vernaillen, Frank and Annaert, Wim and Lambrechts, Diether and Boecxstaens, Veerle and Saeys, Yvan and van den Oord, Joost and Bosisio, Francesca and Karras, Panagiotis and Shain, A Hunter and Bosenberg, Marcus and Leucci, Eleonora and Paschen, Annette and Rambow, Florian and Bechter, Oliver and Marine, Jean-Christophe},
  title = {A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {1},
  pages = {166--183.e25},
  doi = {10.1016/j.cell.2023.11.037}
}
Kostenlos starten →